Table: Anges -2024 group forecast
Mar 14 (Reuters) -
Anges, Inc.
CONSOLIDATED EARNINGS ESTIMATES
(in billions of yen unless specified)
Full Year to Full Year to
Dec 31, 2024 Dec 31, 2024
LATEST PREVIOUS
FORECAST FORECAST
Sales 600 mln 530 mln
Operating loss 8.45 loss 8.50
Recurring loss 8.45 loss 8.50
Net loss 8.65 loss 8.70
EPS loss 43.58 yen loss 43.84 yen
NOTE - Anges, Inc..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4563.T
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001